Search the Community

Showing results for tags 'pdufa'.


More search options

  • Search By Tags

    Type tags separated by commas.

  • Search By Author

Content Type


Categories

  • Biotech Event Tracker

Forums

  • Biotech Stocks
    • General Biotech Investing Discussion
    • Daily Biotech Stock News
    • Biotech Forecast Course Discussion
  • Clinical, Regulatory and Company Catalysts
    • Event Tracker Discussion
    • Suggest Events to Add to the Event Tracker
  • BiotechForecast.com Site Updates, Announcements, & Questions
    • Site Updates & Announcements

Categories

  • Files
  • Image Processing

Found 5 results

  1. Saint-Genis-Pouilly, France - June 27, 2016 – Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (“AAA” or “the Company”), an international specialist in Molecular Nuclear Medicine (MNM), today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s New Drug Application (NDA) and granted Priority Review for Lutathera, a Lu-177-labeled somatostatin analogue peptide currently under development for the treatment of gastro entero pancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adults. The Prescription Drug User Fee Act (PDUFA) target action date is December 28, 2016.